Drug Trial Radar · NCT00083993
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,236
Actual
Start
May 2004
Primary completion
Oct 2006
Study completion Oct 2006
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 8, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this clinical research study, postmenopausal subjects with metastatic breast cancer will be given either the combination of temsirolimus (CCI-779) and letrozole or a placebo and letrozole in first-line hormonal treatment. The primary endpoint of this study is to determine overall progression free survival. Individual subjects will participate in the active treatment phase of the study until disease progression or withdrawal of consent, provided that test article is being tolerated. All subjects will be asked to participate in the long-term follow-up phase of the study, which includes follow-up every 3 months until disease progression (for subjects who withdraw for reasons other than documented progressive disease) or until any new cancer treatment is received, and for survival. The estimated duration of study participation is 34 months.
Conditions
- Breast Neoplasms
- Neoplasm Metastasis
Interventions
Temsirolimus (CCI-779) for 34 monthsDrug
Letrozole for 34 monthsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine overall progression free survival.
Locations
129 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Hoover, Alabama
Site not named
Huntsville, Alabama
Site not named
Tucson, Arizona
Site not named
Jonesboro, Arkansas
Site not named
Burbank, California
Site not named
Campbell, California
Site not named
Fountain Valley, California
Site not named
Gilroy, California
Site not named
Glendora, California
Site not named
Modesto, California
Site not named
Montebello, California
Site not named
Pomona, California
Site not named
Poway, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Santa Rosa, California
Site not named
Soquel, California
Site not named
Vista, California
Site not named
Lakewood, Colorado
Site not named
Norwalk, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Boca Raton, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Hollywood, Florida
Site not named
Jacksonville, Florida
Site not named
Jacksonville, Florida
Site not named
Lake Worth, Florida
Site not named
Miami Shores, Florida
Site not named
New Port Richey, Florida
Site not named
Plantation, Florida
Site not named
Sarasota, Florida
Site not named
Zephyrhills, Florida
Site not named
Atlanta, Georgia
Site not named
Columbus, Georgia
Site not named
Roswell, Georgia
Site not named
Thomasville, Georgia
Site not named
Coeur d'Alene, Idaho
Site not named
Centralia, Illinois
Site not named
Skokie, Illinois
Site not named
Skokie, Illinois
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.